Informações:
Falhas:
ID
21545
Descrição
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00193492
Link
https://clinicaltrials.gov/show/NCT00193492
Palavras-chave
Versões (1)
- 26/04/2017 26/04/2017 -
Transferido a
26 de abril de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Lymphoma, Follicular NCT00193492
Eligibility Lymphoma, Follicular NCT00193492
- StudyEvent: Eligibility
Similar models
Eligibility Lymphoma, Follicular NCT00193492
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
criteria Fulfill
Item
to be included in the study, you must meet the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,2])
Follicular Lymphoma Ann Arbor lymphoma staging system Biopsy sample
Item
follicular nhl, grades 1 or 2 confirmed by a biopsy sample
boolean
C0024301 (UMLS CUI [1,1])
C0432516 (UMLS CUI [1,2])
C0677862 (UMLS CUI [1,3])
C0432516 (UMLS CUI [1,2])
C0677862 (UMLS CUI [1,3])
Age
Item
18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Disease Progression Evidence of
Item
evidence of disease progression at time of study entry
boolean
C0242656 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0332120 (UMLS CUI [1,2])
Chemotherapy Regimen Quantity
Item
must have had at least one previous chemotherapy regimen and not more than two previous chemotherapy regimens.
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
rituximab Treatment completed | Disease Progression Duration
Item
patients who have received previous rituximab are eligible as long as progression occurred more than six months following completion of previous rituximab therapy.
boolean
C0393022 (UMLS CUI [1,1])
C0580352 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0580352 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Measurable Disease | Evaluable Disease
Item
measurable or evaluable disease
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
C1516986 (UMLS CUI [2])
Activities of Daily Living Perform Able
Item
able to perform activities of daily living without considerable assistance
boolean
C0001288 (UMLS CUI [1,1])
C0884358 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0884358 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
Bone Marrow function | Renal function | Liver function
Item
adequate bone marrow, kidney, and liver function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Informed Consent
Item
signed informed consent obtained prior to initiation of any study-specific procedures or treatment.
boolean
C0021430 (UMLS CUI [1])
Study Subject Participation Status
Item
you cannot participate in the study if any of the following apply to you:
boolean
C2348568 (UMLS CUI [1])
Chemotherapy Regimen Quantity
Item
treatment with more than two previous chemotherapy regimens
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
bevacizumab | Bevacizumab Pharmaceutical Preparations Similar
Item
prior treatment with bevacizumab or other similar agents
boolean
C0796392 (UMLS CUI [1])
C0796392 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C2348205 (UMLS CUI [2,3])
C0796392 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C2348205 (UMLS CUI [2,3])
rituximab | Non-Hodgkin Lymphoma Progressive
Item
progressive nhl less than 6 months after receiving previous rituximab
boolean
C0393022 (UMLS CUI [1])
C0024305 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
C0024305 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
Therapeutic procedure Quantity Investigational New Drugs
Item
more than 1 prior treatment with investigational agents within 4 weeks prior to entering this study
boolean
C0087111 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
Non-Hodgkin Lymphoma Metastatic malignant neoplasm to brain | Non-Hodgkin Lymphoma CNS metastases
Item
spread of nhl to brain or nervous system
boolean
C0024305 (UMLS CUI [1,1])
C0220650 (UMLS CUI [1,2])
C0024305 (UMLS CUI [2,1])
C0686377 (UMLS CUI [2,2])
C0220650 (UMLS CUI [1,2])
C0024305 (UMLS CUI [2,1])
C0686377 (UMLS CUI [2,2])
Disease Uncontrolled High risk Complication for medication therapy | Medical condition High risk Complication for medication therapy
Item
history of any other uncontrolled or significant disease or medical condition that may put them at high risk for treatment complications with these agents
boolean
C0012634 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0332167 (UMLS CUI [1,3])
C3266693 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0332167 (UMLS CUI [2,2])
C3266693 (UMLS CUI [2,3])
C0205318 (UMLS CUI [1,2])
C0332167 (UMLS CUI [1,3])
C3266693 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0332167 (UMLS CUI [2,2])
C3266693 (UMLS CUI [2,3])
Clinical Trial Eligibility Criteria Additional
Item
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have. you can then decide if you wish to participate.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])